GRM's new contracts are worth "up to" $6 million a year. Humanoid's Formic release gives no number for Humanoid
Global Receivables Management announced in November contracts it signed in October, with unnamed clients and an estimated margin. Humanoid Global celebrated a portfolio company's US$50 million round without saying what it owns. Lincoln's reverse takeover has an exchange ratio and no valuation.
November 3, 2026 at 5:05 p.m. EST · 2 min read

Three technology releases, each with a large number in the headline and a smaller one in the text.
Global Receivables Management: "up to"
Global Receivables Management (TSXV: GRMI) announced on November 2 that it "entered into receivables management and collection services contracts" with new clients on October 2. It says they could bring "up to $6.0 million in annualized revenue" once fully onboarded, based on the clients' anticipated placement volumes. Onboarding is expected to start in Q4 2026. The clients are not named, and neither is the number of them.
The company estimates a 15% net margin. By our arithmetic that is up to about $0.9 million a year of net profit at full volume. The release sets the new revenue against 2025 revenue cycle management revenue of $69.7 million, an increase of about 8.6%. Its own caution: actual revenue "may be materially lower."
Humanoid Global: a portfolio company's raise
Humanoid Global (CSE: ROBO) put out a release about Formic, which "has raised US$50 million in growth capital" in "a Series B equity round led by Mercato Partners." Humanoid "holds a minority equity interest." The release gives no percentage, no cost and no carrying value, and does not say whether Humanoid took part in the round. Its CEO says "this progress is reflected in the value of our position," without a number. The operating figures quoted for Formic come with a note that "The Company has not independently verified such information."
Lincoln Ventures and Aegis Medical: a ratio, not a price
Lincoln Ventures (TSXV: LX.H) signed a binding agreement to acquire Aegis Medical Innovations, a private BC cardiovascular device company. Lincoln would issue "3.22 common shares of Lincoln per one Aegis share" for "36,823,916 Aegis shares." By our arithmetic that is about 118.6 million Lincoln shares. Aegis holders would own 60% of the renamed Sierra Medical Innovations, subject to the financings. "The Transaction will constitute a reverse takeover."
The money: a C$300,000 bridge at C$0.05, "resulting in the issuance of 6,000,000 common shares," and a C$6,950,000 concurrent financing whose terms "are to be determined." Up to C$1 million goes "directly into Aegis" for a CE mark trial and manufacturing. No valuation is stated for either company, and "Lincoln does not anticipate seeking shareholder approval for the Transaction." The release says the deal "is expected to be an arm's length transaction" under exchange policy. Lincoln holders would end up with 40% of the company, by our arithmetic, without a vote.
More from the Technology Desk
Pivotree calls a 20% revenue drop 'stabilizing' as its bank line is halved. Intermap's acquisition takes $7.7 million of a $12 million balance
Technology Desk · 10h ago

Pelican AI hires Machai for C$320,000 over three months as it lists in Frankfurt. Metatek's guidance needs its best quarter ever, by a wide margin
Technology Desk · 4d ago

WELL posts record revenue and a C$135.5 million loss, and its new guidance implies a smaller fourth quarter. VerticalScope signs two AI labs it will not name
Technology Desk · 7d ago
